ReviewBiosensors2026
Plasmonic Nanoarray Biosensors for Non-Invasive Cancer Diagnostics.
Review in Biosensors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Early cancer detection can expand treatment options and improve patient survival, but it requires tests that can be repeated with minimal patient burden. Urine and saliva can be collected non-invasively and may contain cancer-associated nucleic acids, proteins, and extracellular vesicles. Clinical analysis of these body fluids is complicated by low biomarker abundance, inter-individual variation, and matrix components that interfere with surface-based sensing. Plasmonic nanoarray biosensors address some of these analytical constraints by concentrating local electromagnetic fields, supporting multiplexed optical readout, and accommodating surface chemistry and microfluidic handling. This review examines nanoarray architectures, fabrication methods, surface functionalization, and signal generation for cancer-associated biomarkers in urine and saliva. Localized surface plasmon resonance, surface-enhanced Raman scattering, and metal-enhanced fluorescence are discussed together with applications to bladder, prostate, pancreatic, oral, and head-and-neck cancers. Remaining barriers include biofouling, pre-analytical variation, fabrication reproducibility, limited validation using authentic biofluids, and incomplete sample-to-answer integration. Addressing these challenges through standardized biofluid processing, scalable nanoarray fabrication, and integrated microfluidic platforms will be essential for translating plasmonic nanoarray biosensors into clinically applicable cancer screening tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.